« Back
Home /
Gemcitabine

Gemcitabine

Item no.	HY-17026-5g
Manufacturer	MedChem Express
CASRN	95058-81-4
Amount	5 g
Quantity options	100 mg 10 mM/1 mL 1 g 200 mg 500 mg 5 g
Category	Oncology Metabolism Diabetes Inhibitors & Compound Libraries Small Molecules By Organ Lung Cancer Bladder Cancer Breast Cancer
Type	Inhibitors
Specific against	other
Purity	99.94
Citations	[1]Wang H, et al. Enhanced efficacy of Gemcitabine by indole-3-carbinol in pancreatic cell lines: the role of human equilibrativenucleoside transporter 1. Anticancer Res. 2011 Oct;31(10):3171-80.\|[2]Yip-Schneider MT, et al. Dimethylaminoparthenolide and Gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancer. BMC Cancer. 2013 Apr 17;13:194.\|[3]Gagnadoux F, et al. Safety of pulmonary administration of gemcitabine in rats. J Aerosol Med. 2005 Summer;18(2):198-206\|[4]Yusheng Cai, et al. Elimination of senescent cells by β-galactosidase-targeted prodrug attenuates inflammation and restores physical function in aged mice. Cell Res. 2020 Jul;30(7):574-589. ACS Biomater Sci Eng. 2025 Jan 14.\|Acta Biochim Biophys Sin. 2021 Jan 12;gmaa177.\|Acta Pharmacol Sin. 2023 Dec 6.\|Adv Mater. 2021 May;33(18):e2100949.\|Adv Sci (Weinh). 2023 Feb 19;e2206004.\|Adv Sci (Weinh). 2023 Oct 22:e2302498.\|Adv Sci (Weinh). 2023 Sep 3;e2303872.\|Adv Sci (Weinh). 2024 Aug 23:e2400156.\|Adv Sci (Weinh). 2024 Nov 28:e2407519.\|Adv Sci (Weinh). 2025 Jan 21:e2409173.\|Adv Ther. 2024 Jul 18.\|Aging. 2020 Aug 28;12(16):16304-16325.\|Am J Cancer Res. 2020 Nov 1;10(11):3896-3910.\|Am J Cancer Res. 2020 Apr 1;10(4):1182-1193.\|Arch Toxicol. 2023 Dec;97(12):3209-3226.\|ÁREA DE FARMACIA Y TECNOLOGÍA FARMACÉUTICA. DEPARTAMENTO DE INGENIERÍA. 2020 Oct.\|Biochem Pharmacol. 2020 Jun 6;114085. \|Biochem Pharmacol. 2021 Oct 18;193:114813.\|Biochem Pharmacol. 2024 Apr 24:116234.\|Biol Pharm Bull. 2021 Dec 22.\|Biomaterials. 16 September 2022.\|Biomed Pharmacother. 2019 Sep;117:109185.\|Biomed Pharmacother. 2022 Feb 11;148:112713.\|Biomed Pharmacother. 2023 Aug 31;166:115389.\|bioRxiv. 2023 Feb 28.\|bioRxiv. 2023 Feb 7.\|bioRxiv. 2023 Sep 5.\|bioRxiv. 2024 Aug 6:2024.03.21.586169.\|bioRxiv. 2024 June 12.\|bioRxiv. 2025 February 22.\|bioRxiv. 2025 Jan 27:2025.01.26.634889.\|bioRxiv. 2025 January 02.\|Breast Cancer Res Treat. 2023 May 19.\|Cancer Lett. 2022 Jun 28;536:215651.\|Cancer Lett. 2022 Nov 24;216023.\|Cancer Lett. 2024 Oct 2:217284.\|Cancer Lett. 2025 Mar 14:217633.\|Cancer Med. 2019 Oct;8(13):5903-5915.\|Cell Death Dis. 2025 Jan 18;16(1):28.\|Cell Death Discov. 2021 May 1;7(1):89.\|Cell Mol Life Sci. 2021 Oct 13.\|Cell Mol Life Sci. 2024 Oct 5;81(1):417.\|Cell Oncol (Dordr). 2025 Feb 4.\|Cell Prolif. 2021 Apr 1;e13038.\|Cell Rep Med. 2023 Jan 10;100911.\|Cell Rep Med. 2023 Oct 17;4(10):101234.\|Cell Rep. 2022 Aug 16;40(7):111194.\|Cell Rep. 2024 Apr 23;43(4):114088.\|Cell Res. 2020 Jul;30(7):574-589.\|Chem Biol Interact. 2018 Jun 25;290:44-51.\|Chem Eng J. 2023 Nov 17, 147466.\|Chem Eng J. 2024 Sep 1.\|Chin Chem Lett. 2017 March.\|Chinese Pharmacological Bulletin. 2017, 33(6): 788-792.\|Clin Transl Oncol. 2022 Jul 19.\|Commun Biol. 2024 Dec 3;7(1):1612.\|Curr Issues Mol Biol. 2024 Dec 11;46(12):13951-13969.\|Discov Oncol. 2025 Jan 3;16(1):3. \|DNA Cell Biol. 2021 Dec 13.\|Elife. 2022 May 3;11:e69255.\|Eur J Pharm Sci. 2025 Jan 1:204:106969. \|Eur Rev Med Pharmacol Sci. 2019 Jan;23(2):649-659. \|Exp Cell Res. 2020 Dec 1;397(1):112335.\|Front Oncol. 2021 Jul 13;11:704042.\|Gastroenterology. 2021 Nov;161(5):1601-1614.e23.\|Heliyon. 2024 June 28.\|Hepatology. 2019 May;69(5):1995-2012. \|Immun Inflamm Dis. 2023 Jun 14.\|Inflamm Res. 2022 Oct 27.\|Int Immunopharmacol. 2023 Jul 27;123:110709.\|Int J Biol Sci. 2022 Jul 4;18(11):4301-4315.\|Int J Biol Sci. 2022; 18(1):43-64.\|Int J Clin Exp Pathol. 2017;10(3):3033-3042.\|Int J Hyperthermia. 2024 Feb 12;41(1):2316085.\|Int J Med Sci. 2022; 19(2): 286-298.\|Invest New Drugs. 2022 Jan 4.\|iScience. 6 September 2022, 105081.\|J Biol Chem. 2017 Jun 2;292(22):9136-9149.\|J Biol Chem. 2023 Jun 28;104984.\|J Biomed Inform. 2023 May 15;104383.\|J Cancer Res Clin Oncol. 2024 Jul 13;150(7):348.\|J Cannabis Res. 2024 May 8;6(1):22.\|J Clin Invest. 2024 Mar 7:e172716.\|J Control Release. 2023 Aug 4;361:161-177.\|J Ethnopharmacol. 2024 Mar 19:328:118075.\|J Exp Clin Cancer Res. 2021 Nov 25;40(1):373.\|J Exp Clin Cancer Res. 2022 Oct 5;41(1):293.\|J Exp Clin Cancer Res. 2023 May 4;42(1):111.\|J Immunother Cancer. 2024 Sep 4;12(9):e009318.\|J Mater Chem B. 2023 Oct 11.\|J Med Chem. 2024 Aug 20.\|J Mol Med (Berl). 2019 Aug;97(8):1183-1193.\|J Nanobiotechnology. 2022 Jul 6;20(1):315.\|J Pancreatol. 2023 Dec 12.\|J Pharm Pharmacol. 2025 Jan 23:rgae149.\|J Transl Med. 2023 Nov 21;21(1):838.\|J Transl Med. 2024 Dec 25;22(1):1147.\|J Transl Med. 2024 Dec 3;22(1):1095.\|J Transl Med. 2024 Jan 13;22(1):55.\|MAbs. 2024 Jan-Dec;16(1):2438173.\|Mater Today Nano. 2024 Aug.\|Mol Cancer. 2023 Dec 4;22(1):195.\|Mol Cancer. 2024 Apr 29;23(1):86.\|Mol Cancer. 2024 Jan 10;23(1):12.\|Mol Cancer. 2024 Sep 30;23(1):215.\|Mol Carcinog. 2024 Jan 30.\|Mol Carcinog. 2024 Jul 17.\|Mol Immunol. 2019 May;109:140-148. \|Mol Pharm. 2021 Jun 2.\|Molecules. 2022, 27(20), 6849.\|Nat Commun. 2024 Oct 2;15(1):8540.\|Nat Med. 2024 Mar;30(3):749-761.\|Nature. 2019 Oct;574(7777):264-267. \|Naunyn Schmiedebergs Arch Pharmacol. 2019 May;392(5):615-622.\|Onco Targets Ther. 2020 Sep 28;13:9543-9558.\|Oncogene. 2023 Aug 31.\|Oncol Lett. June 30, 2021.\|Oncol Rep. 2022 Feb;47(2):33.\|Oncol Res. 2024 Nov 13;32(12):1867-1879.\|Oxid Med Cell Longev. 2022 Sep 29;2022:3243647.\|Patent. US20210260092A1.\|Patent. US20220362387A1.\|Patent. US20240344020A1\|Patent. US20240344020A1.\|Pharmacol Res. 2024 May 9:204:107208.\|Phytomedicine. 2024 Apr 26:155656.\|Phytomedicine. 2024 Mar 11, 155527.\|Phytomedicine. 2024 Sep 7:135:156022.\|Phytomedicine. 6 July 2022, 154323.\|Phytother Res. 2022 Aug;36(8):3313-3324.\|Redox Biol. 2021 Jan;38:101807.\|Redox Biol. 2024 May 17:73:103200.\|Res Sq. 2024 Sep 05.\|Research Square Preprint. 2021 Aug.\|Research Square Preprint. 2021 Nov.\|Research Square Preprint. 2024 Aug 19.\|Research Square Preprint. 2024 Jan 8.\|Research Square Preprint. 2024 Nov 06.\|Research Square Print. October 6th, 2022.\|RSC Adv. 2022, 12, 28104-28112.\|Sci Adv. 2024 Dec 13;10(50):eadq4274.\|Sci Adv. 2024 Jul 5;10(27):eadl1197.\|Sci Rep. 2024 Nov 29;14(1):29661.\|Sci Transl Med. 2021 Jan 20;13(577):eaba7401.\|SLAS Discov. 2018 Aug;23(7):687-696. \|Stem Cells Int. 2023 Jan 30.\|Surgery. 2024 Jan 31:S0039-6060(23)00963-7.\|Technol Cancer Res Treat. 2024 Jan-Dec:23:15330338241241935.\|Theranostics. 2021 Mar 24;11(12):5650-5674.\|Transl Lung Cancer Res. 2024 Oct 31;13(10):2698-2712.\|Transl Oncol. 2020 Sep;13(9):100804.\|Transl Oncol. 2023 Oct 26:39:101803.\|Transl Res. 2022.\|Universidad de Granada. 2023 Mar 27.\|University of Brescia. 2023 Feb 2.\|University of Western Australia. 2024 Jul 28.\|View. 2023 Nov 15.\|Acta Biomater. 2023 Apr 21;S1742-7061(23)00220-9.\|Acta Pharm Sin B. 2023 Oct;13(10):4253-4272.\|Adv Sci (Weinh). 2022 May;9(15):e2105894.\|Biomed J. 2020 Aug;43(4):368-374.\|Br J Pharmacol. 2021 Jun;178(12):2496-2515.\|Cancer Lett. 2024 Feb 6:587:216696.\|Cancer Res. 2023 Jun 16;CAN-22-3346.\|Chem Biol Interact. 2023 Nov 22:110816.\|Heliyon. June 2022, e09643.\|Int J Cancer. 2024 Jul 15;155(2):324-338.\|Int J Nanomedicine. 2023 Jul 19.\|J Gastroenterol. 2025 Jan 31.\|J Mol Med (Berl). 2019 Aug;97(8):1183-1193.\|J Pharmacol Exp Ther. 2018 Oct;367(1):20-27.\|JCI Insight. 2022 Oct 13;e159419.\|Molecules. 2023 Nov 12, 28(22), 7552.\|Onco Targets Ther. 2019 Jun 12;12:4585-4593. \|Oncol Lett. 2023 Sep 20.\|Oncotarget. 2017 Oct 6;8(52):90185-90196. \|PLoS Negl Trop Dis. 2019 Aug 20;13(8):e0007681. \|SSRN. 2024 Mar 14.\|Urol Oncol. 2021 Mar;39(3):194.e1-194.e7.
Smiles	NC(C=CN1[C@H]2C(F)(F)[C@H](O)[C@@H](CO)O2)=NC1=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	LY 188011
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	Apoptosis; Autophagy; DNA/RNA Synthesis; Nucleoside Antimetabolite/Analog
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, protect from light)
Molecular Weight	263.2
Product Description	Gemcitabine (LY 188011) is a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent. Gemcitabine inhibits DNA synthesis and repair, resulting in autophagyand apoptosis[1][2].
Manufacturer - Research Area	Cancer
Solubility	DMSO: 200 mg/mL (ultrasonic)\|Ethanol: 12.5 mg/mL (ultrasonic)\|H2O: 6.25 mg/mL (ultrasonic; warming)
Manufacturer - Pathway	Apoptosis; Autophagy; Cell Cycle/DNA Damage
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-17026-5g-safety-datasheet.pdf